Roche Says Crenezumab Drug Didn't Slow Alzheimer's Symptoms in Trial
June 16 2022 - 2:06AM
Dow Jones News
By Maitane Sardon
Roche Holding AG said Thursday that its crenezumab drug it is
studying for the treatment of Alzheimer's disease didn't slow or
prevent cognitive decline in patients in a trial.
The trial was conducted in cognitively unimpaired people who
carry a specific genetic mutation which causes early-onset
Alzheimer's disease, the Swiss pharma company said.
"The trial did not demonstrate a statistically significant
clinical benefit in either of its co-primary endpoints assessing
the rate of change in cognitive abilities or episodic memory
function," Roche said.
Write to Maitane Sardon at maitane.sardon@wsj.com
(END) Dow Jones Newswires
June 16, 2022 01:51 ET (05:51 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
